Search

Purpose: To investigate the effects of diets containing intact or hydrolysed proteins from blue whiting (Micromesistius poutassou) on the development of high blood pressure and markers of kidney function in obese Zucker fa/fa rats which are prone to develop hypertension and renal failure., Methods: Male rats were fed isocaloric diets containing either intact blue whiting whole meal (BW-WM), blue whiting protein hydrolysate prepared with Alcalase ® (BW-HA) or blue whiting protein hydrolysate prepared with Protamex ® (BW-HP) as 1/3 of total protein with the remaining 2/3 as casein, or casein as sole protein source (control group). Blood pressure was measured at Day 0 and Day 32. Rats were housed in metabolic cages for 24 h for collection of urine in week 4. After 5 weeks, rats were euthanized and blood was drawn from the heart. The renin and angiotensin-converting enzyme (ACE) inhibition capacities for casein and blue whiting proteins were measured in vitro., Results: The blood pressure increase was lower in rats fed diets containing blue whiting proteins when compared to the control group, whereas markers of kidney function were similar between all groups. The three blue whiting proteins inhibited renin activity in vitro, whereas casein had no effect. The in vitro ACE inhibition was similar for casein, BW-WM and BW-HP proteins, whereas BW-HA protein was less potent., Conclusion: Blue whiting protein feeding attenuated the blood pressure increase in obese Zucker fa/fa rats, possibly mediated through the renin-angiotensin system and without affecting markers of kidney function.

The International Haemovigilance Network (IHN) defines haemovigilance as 'a set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow-up of recipients), intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products, and to prevent their occurrence or recurrence'. IHN, the International Society of Blood Transfusion and World Health Organization work together to support both developing and established haemovigilance systems. Haemovigilance systems provide valuable data on a range of adverse events related to blood donation and clinical transfusion, from donor syncopal events to transfusion-transmitted infections, immunological complications and the impact of human errors. Harmonised definitions for most adverse reactions have been developed and validated internationally. Definitions of pulmonary complications are again under review. Haemovigilance data have resulted in changes in policy, products and practice, and can complement and inform clinical audit and research, leading to improved blood donor safety, optimised product use and better clinical outcomes after transfusion. However, more work is needed. Not all countries have haemovigilance systems in place. More robust data and careful analysis are required to improve the understanding of the causes, occurrence and clinical outcomes of these events. Wider dissemination of results will facilitate health policy development internationally, and implementation of haemovigilance recommendations will support further important progress in blood safety., (© 2019 British Blood Transfusion Society.)

Background: Age-related loss of muscle mass and function is common in older adults, and studies investigating if dietary proteins may protect and possibly build lean body mass are needed. We assessed the feasibility of conducting a nutritional intervention study in older nursing home residents to investigate the effects of fish protein supplementation on markers of glucose metabolism and inflammation., Methods: This was a double-blind randomised controlled pilot study. Twenty-four nursing home residents, without major cognitive impairment, received a daily oral nutritional supplement containing 5.2 g of fish protein or placebo for 6 weeks. Anthropometric measurements were conducted at baseline. Participants were screened for nutritional risk using the Mini Nutritional Assessment and activities of daily living using the Barthel index and dietary intake was registered. Hand grip strength was measured and fasting blood samples collected at baseline and endpoint., Results: Compliance was high and dropout was low, but participant recruitment was challenging. Serum concentrations of monocyte chemoattractant protein-1 decreased, and C-reactive protein increased in the intervention group compared to control, with no changes in markers of glucose metabolism between groups., Conclusion: Conducting a nutritional intervention using fish protein supplementation in older nursing home residents is feasible but should be conducted as a multi-centre study to account for the low recruitment rate observed in the present study. A full-scale study is needed to gain more knowledge on the potential effects of fish proteins on markers of glucose metabolism and inflammation in relation to the age-related loss of muscle mass and function., Trial Registration: ClinicalTrials.gov NCT03529344 18.05.2018 (retrospectively registered)., Competing Interests: The study was conducted in accordance with the guidelines laid down by the Declaration of Helsinki and was approved by the Regional Ethics Committee of Western Norway (approval No.: 2015/75). All participants gave their written informed consent and were explained that they were free to withdraw from the study at any timepoint during the intervention without having to give a reason and without negative consequences for future care.Not applicable.Ola Flesland and Aslaug Drotningsvik are employed by TripleNine Vedde AS (a producer of fish meal and fish oil for the aquaculture, agriculture, pet food industry and for human consumption). Aslaug Drotningsvik holds a position as an industrial Ph.D. candidate at TripleNine Vedde AS in cooperation with the Norwegian Research Council and the University of Bergen. All other authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Proteins from different fish species and different raw materials such as fish fillets and by-products have shown promising cardioprotective effects in rodents and humans, including effects on cholesterol metabolism. Blue whiting is used mainly to produce fish meal for the feed industry and during this production, a water-soluble protein fraction, containing small peptides that are easily absorbed and may hold bioactive properties, is isolated. The effects of water-soluble fish protein on cholesterol metabolism were investigated in twelve male obese Zucker fa/fa rats. Rats were fed diets with water-soluble protein from blue whiting (BWW) as 1/3 of the total protein and the remaining 2/3 as casein (BWW group) or with casein as the sole protein source (control group). After 5 weeks intervention, the BWW group had lower serum total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol concentrations and lower cholesteryl ester concentration compared to controls. Hepatic concentrations of cholesterol, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, and LDL receptors were also lower in the BWW group. The groups had a similar concentration of serum total bile acids and similar fecal excretions of cholesterol and bile acids. To conclude, the BWW diet led to lower concentrations of serum and liver cholesterol in obese Zucker fa/fa rats, probably due to lower hepatic cholesterol synthesis.

Quality assurance of the donor questionnaire and the donor interview must ensure that all relevant questions about donor eligibility are answered and documented in a reliable format. The use of the self explanatory, electronic donor information tool [EDIT], not only provided a harmonized and standardised system of quality assurance but also saved time and can be easily modified as guidelines change. This brief report highlights the principles of this tool and some of its potential benefits, as experienced over the 3 years since its introduction in Norway.

Purpose of Review: Donor selection and viral screening methods combined with pathogen reduction have increased the safety of pooled plasma to a level which makes reintroduction of ABO-universal plasma an important option., Recent Findings: Solvent detergent-treated pooled plasma has proved to be well suited for the production of pathogen-reduced ABO-universal plasma. One such product, Bioplasma FDP, was licensed in South Africa in 1994 and has since 1996 been in successful clinical use. A clinical study with this product and two studies with the European product, Uniplas, have confirmed the efficacy and safety of pathogen-reduced ABO-universal plasma., Summary: Pooling of plasma enables the production of ABO-universal plasma. Pathogen reduction with solvent detergent eliminates lipid-enveloped viruses, whereas neutralizing antibodies in the plasma pool and nucleic acid amplification testing ensures the safety for recognized nonlipid-enveloped viruses. Pooling also eliminates transfusion-associated acute lung injury (the leading cause of plasma transfusion-related death), reduces immunologic/allergic adverse events by 60-80% and standardizes plasma protein content. Thus, in addition to ABO compatibility, pathogen-reduced ABO-universal plasma has important supplementary benefits that improve the product's cost-effectiveness.

This commentary deals briefly with various topics discussed in the recent annual course in Transfusion Medicine, organized by the Norwegian Red Cross Blood Programme.

Unlabelled: Haemovigilance is defined as the collection of information on complications of transfusion, the analysis of the data, and suggestions for improvement in the transfusion service. A national haemovigilance system is of value in identifying possible areas in need of improvement in the national transfusion system. Haemovigilance becomes even more important if the system is used to compare the situation in one country with the situation in other countries, e.g. if the countries differ significantly in products used. The current study focuses on immunological transfusion complications, especially TRALI, as published in haemovigilance reports from Denmark, Norway, Sweden and the UK., Results: In Norway immunological transfusion reactions occurred 96.7 times per 100 000 red cell (RBC) transfusion, 231.1 times per 100 000 thrombocyte (Trc) concentrate transfusion and five times per 100.000 transfusions of solvent detergent treated plasma (SD plasma). Denmark and the UK have similar rates of transfusion reactions to RBC and fresh frozen plasma (FFP), but quite different for Trc (0.5 vs. 4.9 per 100 000). In 49% of reported TRALI the causative product is FFP, but no case of TRALI after SD plasma transfusion has been reported., Discussion: When considering all reports for immunological complications in Norway, the most striking is the very small number of reports related to SD plasma. Comparing data from Denmark and the UK shows a big difference in reactions caused by thrombocyte concentrates that may reflect different production methods in the two countries. TRALI is most often caused by FFP, but has never been reported after SD plasma transfusion. Heamovigilance data can be valuable in choosing the safest products available.

During 2005 Norwegian Transfusion Medicine has faced some new problems, sought new solutions and gained strength. Interactions with the public and the health authorities have been important issues for consideration, which are discussed below.

Important current issues in transfusion medicine in Norway are discussed. Current patient legislation specifically defines blood donors as patients, and blood and blood products are defined as drugs. Donor selection is controversial, especially deferral of all persons born in, or having lived for more than one year in areas with high prevalence of infections that are transmitted by blood. The threshold for becoming a blood donor is high, but registered donors donate frequently, e.g. 2,4 whole blood donations per year on average. Some blood banks have specialized in multicomponent aphereis technology, in particular collection of two units of red cells.

Both red blood cells and platelets undergo lesions upon storage which affect their function and possibly their clinical outcome. Some of these lesions are reversible, others not. Improved additive solutions and leukocyte depletion can delay the appearance of storage lesions. In addition, cellular apoptosis leads to numerous mitochondrial and surface changes during storage which have the potential to induce immune suppression by tuning down the innate immune system. This overview highlights some laboratory and clinical aspects of red cell and platelet storage lesions.

The Norwegian guidelines for transfusion are harmonised in terms of standards with the European directives, but we have two areas where there are substantial differences. First, in Norway a blood donor is defined as a patient in legal terms. Secondly, we have stricter criteria for geographical origin of the people who are allowed to donate blood than most other countries. It is a challenge to provide information stating that these guidelines are related to the risk of transmitting infectious disease rather than discrimination. Increased focus on hemovigilance and closer contact between the blood banks and the national health authorities will be major issues in future work to improve the quality of Transfusion Medicine in Norway.

Background: Microchimerism may play a part in transfusion complications. The aim of this study was to examine whether establishment of post-transfusion microchimerism was related to leukocyte content., Methods: Twenty non-pregnant female patients, without known malignant or immunological diseases, mean age 68 years, receiving 2-4 units of red blood cell concentrates during elective surgery, were included. One or two of the units were from male donors. Ten patients received buffy-coat depleted red blood cell concentrates, leukocyte count 108-109 per unit, and 10 patients received red blood cells leukoreduced by prestorage leukocyte filtration, with a leukocyte count of <106 per unit. EDTA samples were collected in vacuum tubes before and after 1 week and 6 months after transfusion. The tubes were frozen and stored at -400 degrees C. Genomic DNA was isolated and PCR performed using four primer sets amplifying markers on the Y-chromosome., Results: Microchimerism was detected in a total of eight out of the 20 patients. In three patients microchimerism was detected only before transfusion. These patients had given birth to one or two boys each, and had no history of previous transfusion. Two patients receiving buffy-coat depleted red blood cell concentrates and two patients receiving leukoreduced red blood cell concentrates had detectable microchimerism 1 week after transfusion. The age of the transfused red blood cell concentrates was 6, 24, 8 and 7 days, respectively. One patient receiving leukoreduced red blood cell concentrates had detectable microchimerism after 6 months. The age of this concentrate was 22 days., Discussion: This study demonstrates that microchimerism after transfusion does not seem to be dose dependent, and can be induced even by a >3 week old leukoreduced red blood cell concentrate with a very low leukocyte content.

Background: Transferrin receptor mediates cellular uptake of iron, and the expression on cells reflects iron needs and erythropoietic activity. The results of measuring transferrin receptor in serum (sTfR) in blood donors are presented., Study Design and Methods: Haemoglobin, serum-ferritin and sTfR were measured in 172 female and 174 male donors that had donated whole blood six or more times during the previous 3 years and in 96 female and 56 male new donors., Results: Haemoglobin and sTfR were not significant different in new and repeat donors. New donors had significantly higher s-ferritin than repeat donors. Twenty donors had a Hb above the low limit for normal, but below the determined cut-off for donation. Only three of these had high sTfR and/or low serum-ferritin. Hence, of the total 492 donors 3.5% were below the Hb cut-off, but having Hb, s-ferritin and sTfR within normal ranges. 11.6% of new female donors belonged in this category., Conclusion: STfR is better than s-ferritin as a screening for iron deficiency. Most donors with low tissue iron neither have high sTfR, nor anaemia. There is probably no need to have a separate, higher than the lower normal range, requirement for Hb in donors. STfR measurements are probably most valuable in a setting where most donors are repeat donors.

Plasma and red blood cell quality are affected both by citrate concentration and the levels of extracellular leukocyte and platelet derived substances, accumulated during storage of blood. The effect of leukocyte filtration on the storage stability of whole blood was therefore studied in blood collected in standard CPD and 0.5CPD (CPD with half strength citrate concentration). A total of 52 units, 12 of them with reduced citrate concentration, were leukocyte-filtered with Pall( whole blood filter (WBF1 or 3). No differences in leukocyte or platelet reduction were observed with the two citrate concentrations. However, with 0.5CPD a significantly longer filtration time and increased complement activation was observed. The effect of pre-storage leukocyte filtration on the plasma quality of whole blood was therefore only studied with standard CPDA1 anticoagulant solution (normal strength citrate concentration). Leukocyte filtration did not affect the von Willebrand factor concentration, while a small reduction (7%, p=0.04) in factor VIII (FVIII) concentration was observed. During storage, however, FVIII decreased more slowly in the filtered than in the unfiltered product, and, from day two, the FVIII content was significantly higher in the filtered product (46% versus 30% at 28 days, p<0.001). Factor V (FV) demonstrated a 16% reduction (p<0.001) upon filtration, followed by an additional 8% in the next 24 h and only a 4% reduction the next 27 days, while unfiltered products demonstrated a continuous reduction to 26% at 28 days. While the beta-thromboglobulin (beta-TG) concentration significantly increased (from 836 to 2483 IU/ml, p<0.001) during leukocyte filtration, no further increase was observed during storage. In contrast, unfiltered products demonstrated an increase to 5762 IU/ml (p<0.001) at 14 days, followed by a slight, not significant, reduction. This indicates platelet activation during filtration and explains a parallel reduction in FV. Filtration induced no increase in prothrombin fragment 1+2, while a slight increase was observed in some unfiltered products after 28 days of storage.Pre-storage leukocyte depletion thus improves the coagulation factor content of plasma in stored whole blood.

After solid organ transplantation donor lymphocytes have been shown to survive and multiply in the organ recipient for a prolonged period. It is not clear whether this chimerism detected is the result of immunosuppression or the cause of allograft acceptance. The number of cells transferred, as well as the type of cells, and the degree of activation are likely to be of importance for the establishment of microchimerism. The cells that are flushed out of the vascular tree may be of particular importance since when an antigen primarily bypasses or secondarily avoids organised lymphoid collections, the immune system in the recipient may remain or become "indifferent" to its presence. In the present study we examined the amount of residual donor blood cells that we could flush out from the vascular tree of living donor kidneys and cadaveric donor kidneys immediately prior to transplantation, with special emphasis on T and B lymphocytes. Our study shows that perfusion of donor kidneys just prior to transplantation releases from 0.1 to 1.8x10(6) B-lymphocytes, with an average of 0.7x10(6) and from 0.5x10(6) to 2.6x10(6) T-lymphocytes, with an average of 1.8x10(6), for CD kidneys, and somewhat less for LD kidneys. These cells would otherwise have been flushed out into the organ recipient's circulation, where they might play a role in the establishment of microchimerism.

The establishment of the Norwegian Fractionation Project (Project) was of major importance in preserving national self-sufficiency when plasma, cryoprecipitate and small batch factor IX-concentrates were replaced by virus inactivated products in the last part of the 1980s. Fractionation was performed abroad by contract with Octapharma after tenders on the European market. All Norwegian blood banks (>50) participated in the Project. Total yearly production was 50-60 tons of mainly recovered plasma. From 1993 solvent detergent (SD) treated plasma has replaced other plasma for transfusion. The blood banks paid for the fractionation and/or viral inactivation process, while the plasma remained the property of the blood banks and the final products were returned to the blood banks. The Project sold surplus products to other Norwegian blood banks and the majority of the coagulation factor concentrates to The Institute of Haemophilia and Rikshospitalet University Hospital. Both plasma and blood bank quality was improved by the Project. Clinical experience with the products has been satisfactory and self-sufficiency has been achieved for all major plasma proteins and SD plasma, but a surplus exceeding 3 years consumption of albumin has accumulated due to decreasing clinical use.The Project has secured high yields of the fractionated products and the net income from the produced products is NOK 1115 (140 Euros or US dollars) per litre plasma. An increasing surplus of albumin and the possibility of significant sales abroad of currently not fractionated IVIgG, could lead to a reorganisation of the Project from that of a co-ordinator to a national plasma handling unit. This unit could buy the plasma from the blood banks and have the plasma fractionated by contract after tender, before selling the products back for cost recovery. The small blood banks could produce plasma for products for the Norwegian market, while surplus products from the larger blood banks which are certified for delivery of plasma for fractionation of products to be consumed in the European Community, could be sold on the international market., (Copyright 2003 Elsevier Science Ltd.)

In a prospective study of 16,756 consecutive blood donors, we found 54 donors (0.3%) to be anti-hepatitis C virus (HCV)-positive by a first-generation enzyme-linked immunosorbent assay. After retesting, 18 donors were confirmed positive or indeterminate by a second-generation recombinant immunoblot assay. Sixteen of these donors were found positive by a second-generation enzyme-linked immunosorbent assay, and 15 of these were positive by HCV polymerase chain reaction with two primer sets. Nine donors (50%) had a history of drug abuse. In 15 donors found positive by a second-generation enzyme-linked immunoblot assay liver biopsy specimens were taken after at least 6 months' follow-up. In all except one hepatitis C RNA-negative donor, histologic abnormalities were observed, even when alanine aminotransferase (ALAT) levels were continuously normal or only moderately elevated. The abnormalities were less pronounced in these donors (n = 5) than in donors with ALAT levels increased more than twice the upper normal limit (p < 0.05). In conclusion, we found the proportion of previous drug abusers in anti-HCV-positive blood donors to be high. We confirm that the presence of anti-HCV (second generation) usually, and HCV-RNA always, seems to indicate ongoing infection--also when ALAT levels are normal. Our study further suggests that low-activity hepatitis, evaluated by ALAT levels, may indicate a milder disease.

In a patient, at revisional Christiansen total hip arthroplasty, silver-impregnated bone cement was used as prophylaxis against deep infection. Five years later the patient developed serious neurological deficits, and the prosthesis was loose. The loose Christiansen prosthesis and the silver-impregnated bone cement were removed and a Charnley prosthesis inserted. Intra-operatively the concentration of silver in fluid drawn from the hip joint was assessed to be about 1000 times the normal serum reference value, and tissue samples from the acetabulum were densely impregnated with silver. During the following 2 years the serum concentration of silver decreased from more than 60 times to 20 times the normal; simultaneously the patient partially recovered from her grave muscle paralysis.

Female blood donors with serum ferritin < or = 20 micrograms l-1 and haemoglobin > 120 g l-1 participated in an iron supplement study with two different low-dose supplements in a period without donations. Comparable non-donors served as controls. Serum ferritin, haemoglobin and transferrin were determined. Increases in serum ferritin and in haemoglobin, and decrease in transferrin were highly significant (p < 0.01) in both donor groups. In one of the non-donor groups the increase in serum ferritin and decrease in transferrin were highly significant (p < 0.01), while in the other only transferrin changed significantly (p < 0.03). The increases in serum ferritin and haemoglobin over a 5-month period were significantly higher among donors (p < 0.001) than among non-donors. We interpret the results to mean that the donors have a more efficient iron absorption.

Quality control of leucocyte depleted blood products has become a problem since the introduction of bedside leucocyte filtration. At our Blood Centre, this problem has been circumvented by testing a sample taken as the filtration is completed by sealing off a 10 cm piece of tubing just under the filter. We have tested four brands of erythrocyte filters, Pall RC100, Erypur Optima b, Sepacell R-200A and Sepacell R-500A(II) using two erythrocyte concentrates for each filter. We have tested two brands of thrombocyte filters, Pall PL100 with 6-8 thrombocyte concentrates, and Sepacell PL-5A with 2-6 concentrates. No transfusion should give more than 5 x 10(6) leucocytes. Pall PL100, Pall RC100 and Sepacell R-500A(II) met the criteria.

Serum ferritin levels were measured in 613 women and 376 men included in our Blood Donor Registry in 1990, prior to their first donation. The mean serum ferritin was 34 micrograms/l in females and 98 micrograms/l in males. For men less than 20 years of age mean serum ferritin was 52 micrograms/l which is significantly lower than for the other age groups. For women greater than or equal to 50 years of age mean serum ferritin was 61 micrograms/l, which is significantly higher than for the younger age groups. In 22% of the women and 1.3% of the men serum ferritin was less than 15 micrograms/l upon registration. Female blood donors with an initial serum ferritin of less than 10 micrograms/l had donated on average 1.2 times 11 to 23 months later, and 56% were temporarily or permanently deferred from donation. Females with an initial serum ferritin of between 30 and 39 micrograms/l had donated 2.5 times, and 26% were deferred.

In analyses of cost-effectiveness it is customary to count knowledge of having a high serum cholesterol level as a negative factor. There is little support for this practice in the literature. We have studied the attitude of 305 Norwegian blood donors towards cholesterol testing. 63% stated that they were interested in their serum cholesterol level, and 40% said they knew their own serum cholesterol level. The attitude towards cholesterol testing was clearly positive, both among men and among women, regardless of age. Only one donor stated that she did not want to have her serum cholesterol tested in conjunction with blood donation.

Serum cholesterol levels were measured in 280 blood donors between November 1988 and May 1989 and again between February and April 1991. In 84 of these persons the cholesterol level was also measured between November 1989 and January 1990. The 122 females showed a 9.6% reduction in mean serum cholesterol from 5.8 mmol/l in the first sample to 5.2 mmol/l in the final sample. The 158 males showed a 7.4% reduction from 5.7 to 5.3 mmol/l. Females with initial values greater than 6 mmol/l showed an average reduction in serum cholesterol of 15.2%. For males with initial values greater than 6 the reduction was 14.0%. There was no difference in reduction between those whose cholesterol was measured at the beginning and the end of the study and those whose cholesterol was also controlled during the course of the study. Our study shows that, in the case of blood donors, a programme involving measuring serum cholesterol and distributing written information can lead to a substantial reduction in serum cholesterol.

In the present study the effect of a change from whole blood to plasma donation on iron stores is investigated by measuring serum ferritin levels. Paired serum samples from 125 plasma donors showed a significant increase in mean serum ferritin level with plasmapheresis. 76% of the plasma donors showed an increase in serum ferritin. For plasma donors the haemoglobin concentration is not related to serum ferritin level and hence to iron stores, and a change in haemoglobin concentration is not related to a change in serum ferritin. Plasma donation is a good alternative to whole blood donation for fertile women and for blood donors opposed to iron supplements.

We present the results from a study of 97 female blood donors who reappeared for donation after giving birth from nine to 60 months before. The donors answered a questionnaire about number of pregnancies, the time since last pregnancy, iron medication before and during pregnancy, and methods of contraception. Serum ferritin was determined in a blood sample drawn before donation. In this group, mean serum ferritin was 21.5 +/- 14 micrograms/l. In a control group consisting of young women who registered as donors the mean serum ferritin was 39.4 +/- 29.4 micrograms/l. There was a decrease in serum ferritin with increasing age and parity. The mean serum ferritin value was higher among women who had taken iron supplements regularly before and during pregnancy than among women who had not taken iron supplements. The differences were statistically significant for iron supplementation during pregnancy. Iron supplements during pregnancy seem justified, but further information should be obtained about necessary does and appropriate time for starting supplementation.

In the present study two patients were studied in detail to estimate the quantity of IgG of donor lymphocyte origin. Using IgG subclass quantitation and Gm haemagglutination inhibition titre, we estimated that up to 3% of IgG found after transplantation may be of donor lymphocyte origin. Analysis of viral antibody patterns by imprint immunofixation suggested polyclonal production of donor-derived antibodies.

We present the results of serum-cholesterol measurements in 956 blood donors and an evaluation of their motivation for dietary changes based on answers to a questionnaire. The mean serum-cholesterol level was 5.5 mmol/l for women and 5.7 mmol/l for men, with an increase in serum-cholesterol with age. Motivation for dietary changes was food, since 85% answered that they would change their diet if their serum-cholesterol was high. 65% of those who knew their serum-cholesterol to be high before this study had changed their diet. 38% of the smokers answered that they would stop smoking if their serum-cholesterol was high. Eight to 14 months later, serum-cholesterol measurements in 201 of the blood donors showed that 72.4% of those with serum-cholesterol greater than 6 mmol/l had changed their diet and that these had reduced their serum-cholesterol by an average 10.6%.

Since 1986, we have performed 26,500 plasma donations at the Red Cross and National Hospital Blood Centre. In conjunction with these donations, 4,000 serum samples from 3,400 donors have been tested for IgG and albumin level. 125 donors who donated plasma regularly were studied further. In this group we found a mean reduction in IgG of 0.3 g/l, but no significant reduction in albumin. Even for donors who donate regularly the mean time interval between donations was more than 40 days. Today's recommendation of regular IgG and albumin control is a result of experiences from twice weekly plasma donations in the USA. We conclude that such testing is unnecessary in Norway.

In the present study we have examined serum ferritin in experienced male and female blood donors and in women who had never donated blood before, but had registered at the Blood Centre as future donors. There was no coincidence between low haemoglobin and low s-ferritin when haemoglobin was within normal range. Iron stores (s-ferritin less than 20 micrograms/l) were reduced in 40% of the female blood donors and in 21% the iron stores (s-ferritin less than 10 micrograms/l were completely empty. 10% of the male donors had iron stores, while in 3% the iron stores were empty. Among the females who had not donated blood, 30% had s-ferritin values below 20 micrograms/l and 6% had values below 10 micrograms/l. We conclude that measuring s-ferritin is a better method of identifying individuals at risk for iron depletion than measuring hemoglobins. A combination of longer intervals between donations and iron therapy may prevent depletion of iron stores in blood donors.

A case of complete fetal heart block associated with intra-uterine growth retardation, SSA- and SSB-antibodies is presented. The fetus died in utero. Autopsy revealed damage to the fetal cardiac conducting system together with severe placental fibrosis and recent infarctions. These findings and a slightly prolonged activated partial thromboplastin time indicated also the presence of the lupus anticoagulant.

Sera from 142 Norwegian couples were assayed for the presence of antibody to Cytomegalovirus. Sixty-four percent were seropositive and the yearly conversion rate was approximately 1.65%. The couples included significantly more seropositive women than men. This may indicate that seropositive men infect seronegative women, while seropositive women seldom infect seronegative men.